E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prophylaxis of A (H1N1) 2009 Pandemic Influenza |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To see if one or more A/H1N1 S-OIV vaccine groups meet CBER criteria for immunogenicity in a population of children ages 3 to < 9 yrs (CBER 2007a) |
|
E.2.2 | Secondary objectives of the trial |
A. To perform pairwise comparisons in all vaccine groups according to 95% confidence intervals
B. To evaluate each A/H1N1 S-OIV vaccine candidate hemagglutination inhibition (HI) assay results according to immunogenicity criteria defined by EMEA recommendations (CHMP 2007, CHMP 2008)
C. To evaluate immunogenicity responses according to seasonal influenza vaccination status (2009/2010 Northern Hemisphere vaccine)
D. To evaluate immunogenicity responses in subjects who are seropositive (A/H1N1 S-OIV HI titer ≥ 1:10) at Baseline (Day 1 (pre-vaccination)) as compared to those who are seronegative (HI titer < 1:10)
E. To evaluate the immunogenicity of one versus two doses of A/H1N1 S-OIV vaccine
F. To evaluate antibody persistence at Day 202 and Day 387
Safety objective
To evaluate safety and tolerability of the A/H1N1 S-OIV vaccine across all vaccine groups
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Males and females ages 3 to < 9 yrs
2. Individuals in good health as determined by the outcome of medical history, physical assessment and clinical judgment of the investigator
3. Documented consent provided by parents or legal guardians after the nature of the study has been explained to them according to local regulatory requirements
4. Individuals and parents/guardians are able to comply with all study procedures and are available for all clinic visits scheduled in the study
5. For individuals 7 yrs of age and older (in US; and according to local practice in ex-US locations), informed assent to participate in the study after the nature of the study has been explained to them in terms they can understand
|
|
E.4 | Principal exclusion criteria |
1. Parents or legal guardians and individuals providing assent who are not able to comprehend and to follow all required study procedures for the whole period of the study
2. Parents or legal guardians and individuals providing assent who do not consent to the retention of the subject’s serum samples after study completion
3. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study
4. Individuals with history or any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study
5. History of any anaphylaxis, serious vaccine reactions, or hypersensitivity to influenza viral proteins, egg proteins (including ovalbumin), thimerosal (including mercury) or sodium ethylmercurothiosalicylate, polymyxin, neomycin, betapropiolactone and nonylphenol ethoxylate/nonoxynol-9 (spermacide).
6. History of any serious disease
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. On Day 43, Day 22, and Day 29
2. On Day 43, Day 22, and Day 29
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. Day 1
2. Day 22
3. Day 29
4. Day 43
|
|
E.5.2 | Secondary end point(s) |
1. On Day 202 and Day 387
2. On Day 43, Day 29 and Day 22
3. On Day 202 and Day 387
4. Day 43/Day 1, Day 22/Day1 and Day 29/Day 1
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Day 1
2. Day 22
3. Day 29
4. Day 43
5. Day 202
6. Day 387 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 8 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial months | 13 |